PepGen Inc. (PEPG)
NMS · Healthcare · Biotechnology
$1.47
-2.65%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$101.0M
Exchange
NMS
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -23.9M | -18.7M | -19.7M | -18.9M |
| Net Income | -23.1M | -18.0M | -18.3M | -17.8M |
| Diluted EPS | $-0.70 | $-0.52 | $-0.27 | $-0.26 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -68.3M | -84.8M | -97.7M | -93.6M |
| Net Income | -69.1M | -78.6M | -90.0M | -89.7M |
| Diluted EPS | $-2.91 | $-3.30 | $-2.85 | $-2.12 |